Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope to shield kidneys in sickle cell disease

NCT ID NCT07175051

Summary

This study is testing if a drug called empagliflozin can help protect the kidneys of people with sickle cell anemia. It will involve 20 adults who already show early signs of kidney damage. Researchers will measure changes in urine and blood tests, and use a special kidney scan, to see if the drug slows the progression of kidney disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALBUMINURIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Illinois Chicago, Sickle Cell Center

    Chicago, Illinois, 60302, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.